At SITC 2025, we shared new data focused on one objective: helping translational and clinical teams generate reliable, reproducible immune measurements in complex trial environments. Our presentations addressed challenges that span specimen degradation, sample processing and high-quality unsupervised data analysis. We also introduced new performance data for TokuTBNK, our standardized whole blood TBNK assay performed in our CLIA-compliant laboratory.
Poster #1291: Comparison of Whole Blood Preservation Methods for Cytometric Analysis
We evaluated whole blood preservation approaches for mass cytometry, including the use of our TokuKit, our 3-step whole blood preservation kit, which preserves immune cell populations and functional markers for months instead of days.
View poster here
Poster #111: Unsupervised clustering analysis identifies novel immune cell population in melanoma patients treated with anti-PD-1 therapy
Using the Teiko Dashboard, we applied unsupervised clustering to cytometry data from melanoma patient samples and identified a previously uncharacterized immune cell population in response to checkpoint inhibitor therapy. This analysis highlighted the value of standardized, high-dimensional datasets for discovering mechanistic signatures that may inform response assessment and outcomes
View poster here
Poster #50: Evaluation of CC-BCT blood collection tubes as a stabilization method for pharmacodynamic flow cytometry in multi-site clinical trials
We assessed Cyto-Chex BCT (CC-BCT) blood collection tubes as a stabilization method for pharmacodynamic flow cytometry across distributed sites. Results demonstrated how stabilized whole blood up to 7 days at room temperature can reduce site-to-site variability, streamline sample handling, and support reproducible PD assessment by cytometry.
View poster here
TokuTBNK is our standardized whole blood TBNK panel designed to make global immune monitoring simple and reproducible. Performed entirely in our CLIA-compliant laboratory, TokuTBNK provides consistent PK and PD cytometry readouts, ensuring reliable, global, regulatory-ready cytometry data for clinical trials.
From a single whole blood draw (using Cyto-Chex® BCT), we saw:
• Stability: 7 days at ambient temperature
• Precision: Average CVs of 6% (intra-run) and 9% (inter-run) across 22 immune cell types
• Speed: PK/PD readouts in 3 days
These results demonstrate how TokuTBNK can reduce operational complexity while improving the quality and reproducibility of trial-critical immune cell population readouts.
Reliable cytometry readouts are central to dose escalation, safety monitoring, and understanding mechanism of action. Our findings show that stabilized whole blood, standardized panels, and high dimensional analysis workflows allow teams to generate high-quality data across multi-site trials, all while ensuring high-quality, reproducible data.
We support biopharma teams with our CLIA-validated off-the-shelf and custom mass and spectral flow cytometry panels, whole blood stabilization kit, and data analysis dashboard
TokuTBNK is now available for trials that require consistent, global PK and PD immune monitoring.
.png)
